Literature DB >> 11513545

TcR-alpha/beta(+) CD4(-)CD8(-) T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis.

J J Bleesing1, M R Brown, J K Dale, S E Straus, M J Lenardo, J M Puck, T P Atkinson, T A Fleisher.   

Abstract

Autoimmune lymphoproliferative syndrome (ALPS), caused by inherited defects in apoptosis secondary to mutations in genes encoding Fas/CD95/APO-1 and Fas ligand (Fasl)/CD95L, is characterized by nonmalignant lymphadenopathy and splenomegaly, increased T cell receptor alpha/beta(+) CD4(-)CD8(-) T cells (alpha/beta(+) double-negative T cells [alpha/beta(+)-DNT cells]), autoimmunity, hypergammaglobulinemia, and cytokine abnormalities. The alpha/beta(+)-DNT cells are immunophenotypically and functionally similar to alpha/beta(+)-DNT cells that accumulate in lpr and gld mice, which bear genetic mutations in Fas and FasL. In these mice, alpha/beta(+)-DNT cells express the B-cell-specific CD45R isoform B220. We show that alpha/beta(+)-DNT cells of ALPS patients, with either Fas or FasL mutations, also express B220. In addition, also similar to LPR/gLD mice, they have an unusual population of B220-positive CD4(+) T cells. B220 expression, together with our finding of characteristic lectin binding profiles, demonstrates that cell surface O-linked glycoproteins have undergone specific modifications, which may have consequences for lymphocyte trafficking, cell-cell interactions, and access to alternative apoptosis pathways. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513545     DOI: 10.1006/clim.2001.5069

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  37 in total

1.  Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation.

Authors:  Aude Magerus-Chatinet; Bénédicte Neven; Marie-Claude Stolzenberg; Cécile Daussy; Peter D Arkwright; Nina Lanzarotti; Catherine Schaffner; Sophie Cluet-Dennetiere; Filomeen Haerynck; Gérard Michel; Christine Bole-Feysot; Mohammed Zarhrate; Isabelle Radford-Weiss; Serge P Romana; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

2.  Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS).

Authors:  David T Teachey; Dana A Obzut; Kelly Axsom; John K Choi; Kelly C Goldsmith; Junior Hall; Jessica Hulitt; Catherine S Manno; John M Maris; Nicholas Rhodin; Kathleen E Sullivan; Valerie I Brown; Stephan A Grupp
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

Review 3.  Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS).

Authors:  Pu Li; Ping Huang; Ye Yang; Mu Hao; Hongwei Peng; Fei Li
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 4.  Laboratory diagnosis of primary immunodeficiencies.

Authors:  Bradley A Locke; Trivikram Dasu; James W Verbsky
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

5.  Role of tissue inhibitor of metalloproteinases-1 in the development of autoimmune lymphoproliferation.

Authors:  Elena Boggio; Manuela Indelicato; Elisabetta Orilieri; Riccardo Mesturini; Maria Clorinda Mazzarino; Maria Francesca Campagnoli; Ugo Ramenghi; Umberto Dianzani; Annalisa Chiocchetti
Journal:  Haematologica       Date:  2010-06-30       Impact factor: 9.941

6.  A rapid ex vivo clinical diagnostic assay for fas receptor-induced T lymphocyte apoptosis.

Authors:  Bernice Lo; Madhu Ramaswamy; Joie Davis; Susan Price; V Koneti Rao; Richard M Siegel; Michael J Lenardo
Journal:  J Clin Immunol       Date:  2012-10-11       Impact factor: 8.317

Review 7.  Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  David T Teachey; Alix E Seif; Stephan A Grupp
Journal:  Br J Haematol       Date:  2009-11-23       Impact factor: 6.998

Review 8.  Diagnosis and management of autoimmune cytopenias in childhood.

Authors:  David T Teachey; Michele P Lambert
Journal:  Pediatr Clin North Am       Date:  2013-10-05       Impact factor: 3.278

9.  Targeting Notch signaling in autoimmune and lymphoproliferative disease.

Authors:  David T Teachey; Alix E Seif; Valerie I Brown; Marlo Bruno; Ralph M Bunte; Yueh J Chang; John K Choi; Jonathan D Fish; Junior Hall; Gregor S Reid; Theresa Ryan; Cecilia Sheen; Patrick Zweidler-McKay; Stephan A Grupp
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

10.  IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome.

Authors:  Omar Niss; Allyson Sholl; Jack J Bleesing; David A Hildeman
Journal:  J Allergy Clin Immunol       Date:  2014-08-28       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.